Advertisement

Pharmaceutisch Weekblad

, Volume 14, Issue 2, pp 55–58 | Cite as

Is Recormon® less painful than Eprex® after subcutaneous administration?

  • M. W. G. Hendriks
  • F. P. J. Peters
  • P. M. Hooymans
  • T. W. M. Van de Wiel
  • D. Janknegt
  • R. Janknegt
  • J. J. H. M. Lohman
Practice/Case Reports

Abstract

In this study, we examined the differences in pain score after subcutaneous injection of the epoetin preparations Eprex® and Recormon®. Patients (n=30) received 5 injections Eprex® and 5 injections Recormon® in a randomized double-blind sequence. 10 Min after receiving the injection the patient was asked to complete a visual and a verbal analogue scale and two descriptive scales. The results of 25 patients were used for statistical evaluation. The overall results indicate that there are significantly more patients reporting pain after subcutaneous injection of Eprex® than after Recormon® (11 versus 2 patients, p <0.05; McNemar test). 12 Patients reported no differences in pain. 43 Out of 123 injections Eprex® and 69 out of 125 injections Recormon® caused no pain (p <0.01; χ2 9.455). For 4 patients Recormon® was significantly (p < 0.05) less painful than Eprex®. It can be concluded that Recormon® may be a less painful alternative for individual patients reporting pain after subcutaneous injection of Eprex®.

Keywords

Epoetin Injections, subcutaneous Pain Rating scales 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Macdougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet 1991;20: 99–113.PubMedGoogle Scholar
  2. 2.
    Faulds D, Sorkin EM. Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis. Drugs 1989;38:863–99.PubMedGoogle Scholar
  3. 3.
    Frenken LAM, Van Lier HJJ, Gerlag PGG, Den Hartog M, Koene RAP. Assessment of pain after subcutaneous injection of recombinant human erythropoietin in haemodialysis patients. BMJ 1991;303:288.PubMedGoogle Scholar
  4. 4.
    Linssen ACG, Spinhoven PH. Pijnmeting in de klinische praktijk [Pain measurement in clinical practice]. Ned Tijdschr Geneeskd 1991;135:557–9.PubMedGoogle Scholar
  5. 5.
    Swinscow TD. Statistics at square one. X-paired alternatives. BMJ 1976;2:225–6.PubMedGoogle Scholar
  6. 6.
    Machin D, Lewith GT, Wylson S. Pain measurement in randomized clinical trials. A comparison of two pain scales. Clin J Pain 1988;4:161–8.Google Scholar
  7. 7.
    Sobota JT. Erythropoietin treatment of end-stage renal disease: North American and Japanese experience. In: Garnick MB, ed. Erythropoietin in clinical applications. An international perspective. New York: Marcel Dekker, 1990:183–219.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1992

Authors and Affiliations

  • M. W. G. Hendriks
    • 1
  • F. P. J. Peters
    • 2
  • P. M. Hooymans
    • 1
  • T. W. M. Van de Wiel
    • 2
  • D. Janknegt
    • 3
  • R. Janknegt
    • 1
  • J. J. H. M. Lohman
    • 1
  1. 1.Department of Clinical Pharmacy and ToxicologyMaasland HospitalMB Sittardthe Netherlands
  2. 2.Department of Internal MedicineMaasland HospitalSittard
  3. 3.Emmenthe Netherlands

Personalised recommendations